For RAS wild-type patients, there was a significant correlation between the efficacy of anti-EGFR mAb (cetuximab) and the tumour site, while no significant correlation between the efficacy of anti-VEGF mAb (bevacizumab) and the tumour site was observed. Here, EGFR is linked to neoplasm.